NeuroWiki contains 531 treatment entries covering drugs, biologics, gene therapies, and device-based interventions across all stages of development for neurodegenerative diseases. This comprehensive pipeline reflects decades of research investment and represents the most robust drug development effort in the field of neurology. The pipeline spans multiple disease categories including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), frontotemporal dementia (FTD), and rare tauopathies such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS)[1].
The current pipeline demonstrates a significant shift from symptomatic treatments toward disease-modifying therapies targeting the underlying pathological mechanisms of neurodegeneration. This transition has been enabled by advances in biomarker development, improved understanding of disease biology, and innovative clinical trial designs that allow for earlier intervention and more precise patient selection[2].
The landscape of approved Alzheimer's disease therapies has evolved dramatically since 2021, with three disease-modifying treatments now available:
Aducanumab (Aduhelm) — Anti-Aβ monoclonal antibody received accelerated approval from the FDA in 2021, representing the first disease-modifying therapy targeting amyloid-beta. The approval was controversial due to conflicting Phase 3 trial results (EMERGE showed cognitive benefit while ENGAGE did not), and the drug was eventually discontinued in 2024. The development program provided valuable lessons about amyloid targeting and dose selection that have informed subsequent programs.
Lecanemab (Leqembi) — Anti-Aβ monoclonal antibody received full FDA approval in 2023 following positive Phase 3 Clarity AD trial results showing 27% slowing of cognitive decline over 18 months. Lecanemab targets protofibrils, the most toxic form of soluble Aβ aggregates, and has demonstrated robust amyloid reduction on PET imaging. The approval represented a watershed moment for AD therapeutics, validating the amyloid hypothesis and establishing a new treatment paradigm[1:1].
Donanemab — Anti-Aβ monoclonal antibody received FDA approval in 2024 based on the TRAILBLAZER-ALZ 2 trial showing significant slowing of cognitive decline in patients with early-stage AD. Donanemab targets amyloid plaques with high specificity and demonstrated the importance of amyloid clearance as a therapeutic endpoint.
Symptomatic treatments continue to play an important role in AD management:
The AD Phase 3 pipeline represents the most robust in neurodegenerative disease drug development, with multiple mechanisms in late-stage development:
| Drug | Mechanism | Company | Target | Status |
|---|---|---|---|---|
| Remternetug | Anti-Aβ mAb | Eli Lilly | Amyloid | Phase 3 (TRAILBLAZER-ALZ 4) |
| Levemelatonin | MT1/MT2 agonist | Neurim | Sleep-wake | Phase 3 |
| Atacicept | TACI-Fc | Merck | B-cell | Phase 3 (ATRAIN) |
| Semaglintide | GLP-1RA | Novo Nordisk | Neuroprotection | Phase 3 (EVOKE/EVOKE+) |
| Blarcamesine | σ1 agonist | Anavex | Neuroprotection | Phase 3 |
Remternetug represents a next-generation anti-amyloid antibody with potentially improved brain penetration and faster amyloid clearance. The ongoing Phase 3 program is evaluating both cognitive and biomarker outcomes in patients with early AD[1:2].
Semaglintide (GLP-1 receptor agonist) represents the growing interest in metabolic approaches to AD. GLP-1 agonists have demonstrated neuroprotective properties in preclinical models through anti-inflammatory, anti-apoptotic, and mitochondrial protective mechanisms. The large-scale EVOKE and EVOKE+ trials will test whether these effects translate to human cognitive benefit[1:3].
Atacicept targets the TACI receptor involved in B-cell activation and antibody production. Given the emerging role of humoral immunity in AD pathogenesis, this represents a novel immunomodulatory approach to disease modification.
The AD Phase 2 pipeline is diverse, spanning multiple mechanism categories:
Anti-tau therapies represent the second major pillar of AD-modifying treatment:
Synaptic plasticity modulators aim to preserve or restore neuronal connectivity:
Neuroinflammation targets address the critical role of microglial activation:
Other notable Phase 2 programs include:
The PD treatment landscape includes both motor and non-motor symptom management:
Motor symptom treatments:
Device-based therapies:
The PD Phase 3 pipeline focuses on disease modification and symptomatic improvement:
Gene therapies represent the most advanced disease-modifying approach:
α-synuclein targeting immunotherapies aim to reduce the pathological protein driving PD:
LRRK2 inhibitors target the most common genetic cause of PD:
GBA modulators address the significant PD risk associated with GBA mutations:
The PD Phase 2 pipeline is extensive and diverse:
Neuroprotective agents:
Targeted approaches:
ALS treatment has evolved significantly in recent years with multiple FDA-approved disease-modifying options:
Riluzole — The first disease-modifying therapy for ALS (1995), reduces glutamate excitotoxicity through multiple mechanisms. Provides modest survival benefit (2-3 months) and remains standard of care.
Edaravone (Radicava) — Antioxidant therapy approved in 2017 based on Phase 3 trial showing reduced functional decline. Represents the first new ALS drug in over 20 years and validates neuroprotective approaches.
Tofersen (Qalsody) — Antisense oligonucleotide targeting SOD1 mutations, approved in 2023 for ALS patients with SOD1 mutations. First genetic therapy for ALS and demonstrates the potential for precision medicine approaches.
Relyvrio (AMX0035) — Combination of sodium phenylbutyrate and taurursodiol, approved in 2022 based on Phase 2/3 trial showing survival benefit. Targets both mitochondrial dysfunction and oxidative stress.
The ALS Phase 3 pipeline addresses both genetic and sporadic forms of the disease:
Antisense oligonucleotides for genetic targets:
Cell-based therapies:
Neuroprotective approaches:
The ALS Phase 2 pipeline includes innovative mechanisms:
The tauopathy pipeline has expanded significantly:
Anti-tau antibodies:
Tau aggregation inhibitors:
Other mechanisms:
The HD pipeline has evolved following the tominersen setback:
Antisense approaches:
Gene editing approaches:
Neuroprotective strategies:
Analysis of the current pipeline reveals therapeutic priorities across mechanisms:
| Mechanism | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Amyloid targeting | 12 | 8 | 4 | 3 |
| Tau targeting | 15 | 10 | 3 | 0 |
| α-synuclein | 8 | 6 | 2 | 0 |
| Neuroinflammation | 20 | 14 | 5 | 1 |
| Neuroprotection | 25 | 18 | 7 | 2 |
| Gene therapy | 15 | 8 | 3 | 0 |
| Mitochondrial | 12 | 9 | 4 | 1 |
| Synaptic | 8 | 6 | 2 | 0 |
The dominance of amyloid and tau targeting in AD reflects the established understanding of AD pathogenesis and the large patient populations enabling clinical trials. Neuroinflammation targeting shows significant growth across all diseases, reflecting the recognition that immune dysfunction is a common pathological feature.
Gene therapy represents a growing segment of the pipeline, with multiple programs reaching late-stage development across AD, PD, and ALS. Advances in AAV delivery, promoter design, and manufacturing have enabled this expansion.
The regulatory environment has become increasingly supportive of neurodegenerative disease therapeutics:
The FDA has granted breakthrough therapy designation to over 40 therapies in the neurodegenerative space, enabling:
The accelerated approval pathway has become increasingly important:
Understanding the clinical development pathway is essential:
| Phase | Patients | Purpose | Timeline | Success Rate |
|---|---|---|---|---|
| Phase 1 | 20-100 | Safety, dosage | 1-2 years | ~70% |
| Phase 2 | 100-300 | Efficacy, side effects | 2-3 years | ~33% |
| Phase 3 | 1000-3000 | Confirm efficacy | 3-5 years | ~25-30% |
| Phase 4 | Post-approval | Long-term effects | Ongoing | N/A |
Neurodegeneration trials face unique challenges including long disease duration, need for biomarkers, patient heterogeneity, and significant placebo responses.
Long disease duration requires:
Patient heterogeneity addressed through:
Biomarker development has enabled:
Adaptive pathways are increasingly employed:
Patient-focused drug development:
The pipeline is expanding beyond traditional small molecules:
Recognition that neurodegeneration involves multiple pathways is driving:
Growing focus on at-risk populations:
Disease-modifying:
Symptomatic:
Novel approaches:
Disease-modifying:
Motor symptoms:
Non-motor:
Approved:
Pipeline:
This page is auto-maintained. Last updated: 2026-03-27
Cummings J, et al. Alzheimer's disease drug development pipeline 2024. Alzheimer's & Dementia. 2024. ↩︎ ↩︎ ↩︎ ↩︎
Park J, et al. Parkinson's disease drug pipeline 2024. Nature Reviews Drug Discovery. 2024. ↩︎